ArticleFrontiers in cardiovascular medicine2025
Real-world procedural and clinical outcomes of contemporary balloon-expandable and self-expandable TAVR systems: a single-center experience.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter aortic valve replacement (TAVR) is rapidly becoming the preferred treatment for patients with severe aortic stenosis across different surgical risk profiles. However, the comparative performance of contemporary balloon-expandable valves (BEVs) and self-expandable valves (SEVs) in real-world practice remains debated. Objectives: To evaluate procedural and postoperative outcomes associated with different contemporary TAVR systems in a consecutive cohort of patients treated at a single center. Methods: We retrospectively analyzed 366 consecutive patients with symptomatic severe aortic stenosis and high surgical risk who underwent TAVR at Casa di Cura San Michele (Maddaloni, Italy) between January 2019 and October 2024. Patient baseline characteristics, procedural data, and in-hospital outcomes were collected and compared across different TAVR systems. Results: Among implanted prostheses, 71.0% were SEVs (Accurate Neo, Evolut R/Pro, Portico, Allegra) and 28.7% were BEVs (Sapien 3, Myval). BEVs were associated with significantly higher post-procedural transvalvular gradients (11.7 vs. 8.5 mmHg, Conclusion: In a real-world, single-center cohort, both BEVs and SEVs provided favorable outcomes. While BEVs demonstrated superior sealing properties with fewer paravalvular leaks, SEVs were associated with lower postoperative gradients. Careful consideration of anatomical and procedural factors remains essential for optimizing outcomes with contemporary TAVR systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.